91 related articles for article (PubMed ID: 21971247)
1. [Epigenome in hematopoietic malignancies].
Iwama A
Rinsho Ketsueki; 2011 Oct; 52(10):1687-95. PubMed ID: 21971247
[No Abstract] [Full Text] [Related]
2. [Identification by epigenome analysis of novel molecular targets for therapy in hematopoietic malignancies].
Nojima M
Rinsho Ketsueki; 2011 Mar; 52(3):111-7. PubMed ID: 21471697
[No Abstract] [Full Text] [Related]
3. [Epigenetics in hematological disorders].
Furukawa Y
Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
[No Abstract] [Full Text] [Related]
4. Role of epigenetic changes in hematological malignancies.
Lehmann U; Brakensiek K; Kreipe H
Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
[TBL] [Abstract][Full Text] [Related]
5. [Molecular basis of hematological malignancies].
Kitamura T; Inoue D; Nakahara F; Okochi N; Kato N; Togami K; Uchida T; Kagiyama Y; Kawabata KC; Nagase R; Horikawa S; Hayashi K; Saika M; Izawa K; Oki T; Chiba S; Harada Y; Harada H; Kitaura J
Rinsho Ketsueki; 2014 Oct; 55(10):1715-23. PubMed ID: 25297732
[No Abstract] [Full Text] [Related]
6. Epigenetic immunomodulation of hematopoietic malignancies.
Gattei V; Fonsatti E; Sigalotti L; Degan M; Di Giacomo AM; Altomonte M; Calabrò L; Maio M
Semin Oncol; 2005 Oct; 32(5):503-10. PubMed ID: 16210091
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic dysregulation in hematological malignancies.
Iwama A
Int J Hematol; 2017 Jan; 105(1):5-6. PubMed ID: 27822916
[No Abstract] [Full Text] [Related]
8. The fundamental role of epigenetics in hematopoietic malignancies.
Galm O; Herman JG; Baylin SB
Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
[TBL] [Abstract][Full Text] [Related]
9. [Analysis for hematopoietic disorder using DNA methylation as a molecular marker].
Uchida T; Fukuda T
Rinsho Ketsueki; 2000 May; 41(5):380-5. PubMed ID: 10879095
[No Abstract] [Full Text] [Related]
10. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
11. Aberrant epigenetic landscape in cancer: how cellular identity goes awry.
Berdasco M; Esteller M
Dev Cell; 2010 Nov; 19(5):698-711. PubMed ID: 21074720
[TBL] [Abstract][Full Text] [Related]
12. [Research on demethylation therapy for hematology malignancy].
Shen JZ; Zhou HR
Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):355-6. PubMed ID: 16780731
[No Abstract] [Full Text] [Related]
13. Genomics in hematologic malignancies.
Foà R; Hoffbrand VA
Rev Clin Exp Hematol; 2005 Jun; 9(1):1 p preceding E1. PubMed ID: 16874950
[No Abstract] [Full Text] [Related]
14. The NIH Roadmap Epigenomics Program data resource.
Chadwick LH
Epigenomics; 2012 Jun; 4(3):317-24. PubMed ID: 22690667
[TBL] [Abstract][Full Text] [Related]
15. Introduction into the analysis of high-throughput-sequencing based epigenome data.
Huss M
Brief Bioinform; 2010 Sep; 11(5):512-23. PubMed ID: 20457755
[TBL] [Abstract][Full Text] [Related]
16. Guest editorial: Genetic and epigenetic alterations in hematopoietic malignancies.
Kitamura T
Int J Hematol; 2013 Feb; 97(2):163-4. PubMed ID: 23397211
[No Abstract] [Full Text] [Related]
17. What an epigenome remembers.
Lange UC; Schneider R
Bioessays; 2010 Aug; 32(8):659-68. PubMed ID: 20658704
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of drug resistance in hematologic malignancies.
Dalton WS
Semin Hematol; 1997 Oct; 34(4 Suppl 5):3-8. PubMed ID: 9408955
[TBL] [Abstract][Full Text] [Related]
19. Molecular tumor classification using DNA methylome analysis.
Sill M; Plass C; Pfister SM; Lipka DB
Hum Mol Genet; 2020 Oct; 29(R2):R205-R213. PubMed ID: 32657331
[TBL] [Abstract][Full Text] [Related]
20. Epigenomics of human colon cancer.
Carmona FJ; Esteller M
Mutat Res; 2010 Nov; 693(1-2):53-60. PubMed ID: 20691710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
